Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$5.53 USD
-0.27 (-4.66%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.49 -0.04 (-0.72%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Recursion Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
RXRX 5.53 -0.27(-4.66%)
Will RXRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Other News for RXRX
Q2 2025 Recursion Pharmaceuticals Inc Earnings Call Transcript
Decoding Recursion Pharmaceuticals Inc (RXRX): A Strategic SWOT Insight
Recursion Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $19. ...
Recursion Sets $100 Million Partnership Goal by 202
Recursion Pharmaceuticals (RXRX) Exceeds Revenue Expectations in Q2